LeonaBio (LONA) Total Non-Current Liabilities (2019 - 2026)

LeonaBio (LONA) reported Total Non-Current Liabilities of $21.1 million for Q1 2026, down 66.54% quarter-over-quarter from $63.0 million in Q4 2025.

LeonaBio (LONA) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends

LeonaBio (LONA) has 3 years of Total Non-Current Liabilities data on file, last reported at $21.1 million in Q1 2026.

Total Non-Current Liabilities for Q1 2026 came in at $21.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $21.1 million (changed N/A YoY), and the FY2025 annual result was $63.0 million, changed N/A from the prior year.
Total Non-Current Liabilities slipped to $21.1 million in Q1 2026 per LONA's latest filing, from $63.0 million in the prior quarter.
Over five years, Total Non-Current Liabilities peaked at $63.0 million in Q4 2025 and troughed at $21.1 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Non-Current Liabilities (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	42,980.09
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	11.03 Mn
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	95.20 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	644,700.00
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	5.87 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	64.76 Mn
10	LeonaBio	154.12 Mn	86.44 Mn	-	21.07 Mn

Download Data